logo-loader
viewFutura Medical PLC

Futura Medical sees 'potentially quicker route to market' for its erectile dysfunction formulation

Futura Medical PLC's (LON:FUM) executive director and head of R&D Ken James speaks to Proactive London's Andrew Scott following the read-out from the phase III clinical trial of its erectile dysfunction gel.

James says while MED2005 showed strong efficacy, excellent safety and rapid speed of onset, the placebo had a “highly statistically significant” impact on the men in the control group of the experiment.

The placebo in this trial was DermaSys, developed by the company to deliver the active ingredient glyceryl trinitrate, or GTN for short.

Quick facts: Futura Medical PLC

Price: 13.18 GBX

AIM:FUM
Market: AIM
Market Cap: £32.37 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Futura Medical's Ken James updates on EU and US regulatory progress for MED3000

Futura Medical PLC's (LON:FUM) Ken James speaks to Proactive London's Andrew Scott after announcing it's submitted the product dossier for its treatment of erectile dysfunction known as MED3000 for marketing approval in Europe. In the US, James says that after a second pre-submission meeting...

2 days, 5 hours ago

2 min read